BrainsWay Reports Strong Q2 2025 Financial Results

Brainsway ( (BRSYF) ) has released its Q2 earnings. Here is a breakdown of the information Brainsway presented to its investors.

BrainsWay Ltd. is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, utilizing its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) technology to address conditions such as major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The company operates primarily in the healthcare sector with a focus on mental health solutions.

In its second quarter of 2025, BrainsWay reported a record quarterly revenue of $12.6 million, marking a 26% increase compared to the same period in 2024. The company also raised its full-year 2025 revenue and EBITDA guidance, reflecting its strong financial performance and strategic growth initiatives.

Key financial highlights include an operating profit of $0.6 million and an adjusted EBITDA of $1.5 million, a 16% increase from the previous year. The net profit surged by 233% to $2.0 million, supported by a 35% increase in the shipment of Deep TMS systems, which now total 1,522 units installed globally. Additionally, BrainsWay has entered into an equity financing transaction with Stella MSO, LLC, and is actively pursuing further strategic investments in high-performing mental health providers.

The company maintains a robust cash position with $78.3 million in cash, cash equivalents, and short-term deposits as of June 30, 2025. BrainsWay is also advancing its clinical trials and regulatory submissions, including data submission to the FDA for an accelerated Deep TMS treatment protocol.

Looking ahead, BrainsWay’s management remains optimistic about the company’s growth trajectory, driven by its strategic initiatives and the expanding adoption of its Deep TMS technology. The company aims to continue building on its strong market position and explore new opportunities to enhance its impact in the mental health sector.